NeuroPace Q2 revenue slightly beats estimates

NeuroPace

11/08/2026 21:23

Overview
US epilepsy device maker's Q2 revenue grew 17% yr/yr, slightly beating analyst expectations
Company raised full-year 2026 revenue guidance
Q2 net loss narrowed from prior year as RNS adoption increased

Outlook
NeuroPace raises 2026 revenue guidance to $99.5 mln-$101.5 mln, up from $99 mln-$101 mln
Company now expects 2026 non-GAAP gross margin of 82.0%-83.0%, up from 81.5%-82.5%
NeuroPace sees 2026 adjusted EBITDA loss of $7.5 mln-$8.5 mln, improved from $8.5 mln-$9.5 mln loss

Result Drivers
RNS ADOPTION - Co said increased adoption of RNS System for focal epilepsy drove Q2 revenue growth
COMMERCIAL EXPANSION - Reached new all-time highs in active prescribers, accounts and patient pipeline

Company press release: ID:nBw6FgZ7Na

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Slight Beat*
$22.83 mln
$22.65 mln (9 Analysts)
Q2 Loss Per Share
 
$0.18
 
Q2 Net Loss
 
$6.20 mln
 
Q2 Gross Profit
 
$18.91 mln
 
Q2 Operating Expenses
 
$24.05 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for NeuroPace, Inc. is $20.00, about 34.4% above its August 10 closing price of $14.88

Reuters Recommended Reads
Aug 10 - Ceribell Q2 revenue beats estimates; raises 2026 revenue outlook
Aug 10 - Tactile Systems Q2 revenue up 9%, slightly beats estimates
Aug 10 - Definitive Healthcare Q2 revenue slightly misses estimates despite customer gains

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)